Cholesterol-Lowering Gene Therapy Counteracts the Development of Non-ischemic Cardiomyopathy in Mice.

about

Targeting Cholesterol in Non-ischemic Heart Failure: A Role for LDLR Gene Therapy?

P2860

Q45873443-D966A79F-DDCE-4860-A4CD-E8AA6E9F6B06

P2860

Cholesterol-Lowering Gene Therapy Counteracts the Development of Non-ischemic Cardiomyopathy in Mice.

Item

http://www.wikidata.org/entity/Q40077690

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Cholesterol-Lowering Gene Ther ...... chemic Cardiomyopathy in Mice.

@en

type

Item

label

Cholesterol-Lowering Gene Ther ...... chemic Cardiomyopathy in Mice.

@en

prefLabel

Cholesterol-Lowering Gene Ther ...... chemic Cardiomyopathy in Mice.

@en

P1476

Cholesterol-Lowering Gene Ther ...... chemic Cardiomyopathy in Mice.

@en

P2093

Andrey Postnov

http://www.w3.org/2001/XMLSchema#string

Bart De Geest

http://www.w3.org/2001/XMLSchema#string

Frank Jacobs

http://www.w3.org/2001/XMLSchema#string

Ilayaraja Muthuramu

http://www.w3.org/2001/XMLSchema#string

Olivier Gheysens

http://www.w3.org/2001/XMLSchema#string

Paul P Van Veldhoven

http://www.w3.org/2001/XMLSchema#string

Tom Dresselaers

http://www.w3.org/2001/XMLSchema#string

P2860

SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth

Cholesterol trafficking is required for mTOR activation in endothelial cells

miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling

TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth

Substrate-enzyme competition attenuates upregulated anaplerotic flux through malic enzyme in hypertrophied rat heart and restores triacylglyceride content: attenuating upregulated anaplerosis in hypertrophy.

Selenoprotein synthesis and side-effects of statins.

Rosuvastatin in older patients with systolic heart failure.

Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.

Hypercholesterolemia is associated with hyperactive cardiac mTORC1 and mTORC2 signaling.

Cardiac-specific deletion of acetyl CoA carboxylase 2 prevents metabolic remodeling during pressure-overload hypertrophy

P304

2513-2525

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.YMTHE.2017.07.017

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Uwe Himmelreich

Ruhul Amin

Joseph Pierre Aboumsallem

Mudit Mishra

P577

2017-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28822689

http://www.w3.org/2001/XMLSchema#string

P921

gene therapy

P932

5675591

http://www.w3.org/2001/XMLSchema#string

Cholesterol-Lowering Gene Therapy Counteracts the Development of Non-ischemic Cardiomyopathy in Mice.

about

P2860

P2860

Cholesterol-Lowering Gene Therapy Counteracts the Development of Non-ischemic Cardiomyopathy in Mice.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932